| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6667050 | APIL | Chewable oral contraceptive |
Apr, 2019
(5 years ago) | |
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(4 years from now) | |
Lo Minastrin Fe is owned by Apil.
Lo Minastrin Fe contains Ethinyl Estradiol; Norethindrone Acetate.
Lo Minastrin Fe has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Lo Minastrin Fe are:
- US5552394
- US6667050
Lo Minastrin Fe was authorised for market use on 24 July, 2013.
Lo Minastrin Fe is available in tablet, chewable, tablet;oral dosage forms.
Lo Minastrin Fe can be used as prevention of pregnancy.
The generics of Lo Minastrin Fe are possible to be released after 02 February, 2029.
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 24 July, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET, CHEWABLE, TABLET;ORAL
LO MINASTRIN FE family patents
